Author: Jesse Landry

There’s something that resonates about a company named Other Half going all in. While most startups are trying to dress up filler as function, these two brought lab coats to a dog park and walked out with a $3 million seed round like it was just another Tuesday. AJ Patel doesn’t miss. After building and exiting Zesty Paws for a tidy $610 million and stacking plays with InstaNatural, Zenwise, and HighKey, he could’ve just sat back and surfed exit waves. Instead, he teamed up with Mike Watts, a quiet killer in consumer packaged goods who’s spent 15+ years shaping food…

NeuroEM just cracked open a new chapter in brain tech, and the stakes aren’t just high, they’re cognitive. Picture this: you’re standing in a world obsessed with treating symptoms while the root cause plays Houdini. Now, in walks NeuroEM Therapeutics, Inc., a clinical-stage disruptor out of Tampa with a device that doesn’t just treat Alzheimer’s but dares to reverse its cognitive grip. Yeah, reverse. Not manage. Not delay. Reverse. And the science behind it? That’s not marketing smoke, it’s electromagnetic fire forged in a lab and tested on human minds. Founded in 2013 by Dr. Gary W. Arendash, Ph.D., a…

Back in 2014, Button launched with a premise most folks in tech weren’t ready for: what happens when you stop obsessing over the click and start fixing the broken junk pile that comes after it? Fast-forward to June 2025, and Button just landed a strategic growth investment from PSG. That’s not just capital, it’s a nod from the grown-ups that the kids who once hacked deep linking are now running mobile commerce like it’s a hedge fund. Silent amount, loud implications. This is fuel for a company already powering $1B+ in monthly commerce and $15B+ overall. Button isn’t playing the…

The next cash crop won’t get you high, but it might elevate your bottom line. Industrial hemp. Not the stoner stereotype. Not the CBD sideshow. The kind that’s grown to fuel tractors, not drum circles. Enter Saluna, a St. Louis-based ag-tech startup that’s quietly building a new playbook for the American farmer, grain-first, data-backed, and genetically dialed in for the heartland. And if you haven’t heard the name yet, don’t worry. You will. They just pulled in $750K, capping a total raise between $2.7M and $3.5M depending on whose receipts you trust. Either way, the runway just got longer, and…

There’s a difference between building an MSO and building a movement, and Allied OMS isn’t in this game for a participation trophy. While most folks are still trying to paste clinical care to an Excel sheet and call it “strategy,” Allied OMS has been quietly running the kind of blueprint that makes PE firms perk up and surgeons lean in. This week? That quiet just turned into a roar. A strategic growth investment from 65 Equity Partners, with Everberg Capital rolling in as co-pilot, marks Allied OMS’ first institutional capital raise. But make no mistake, this isn’t a typical check-drop.…

When you name your company Corvia Medical, Latin for “heart,” you’d better come correct. And on June 17, 2025, Corvia Medical didn’t just show up, they stepped in with $55 million in backing from a crew that’s seen the future and doubled down: Third Rock Ventures, General Catalyst, AccelMed, Lumira Ventures, and two strategic backers who clearly prefer to play silent but deadly. Let’s cut through the standard medtech noise. Corvia isn’t chasing the tail lights of yesterday’s cardiology. They’re rewriting pressure relief, literally. Their flagship, the Corvia Atrial Shunt System, creates a controlled passage from left to right atrium,…

Most people hear “military planning” and picture a room full of tired faces, stale coffee, and PowerPoint decks that haven’t seen daylight since Windows XP. But Onebrief? They didn’t just build a better workflow, they built a war fighting operating system. And the DoD’s buying what they’re selling. Yesterday, the Honolulu-based defense tech startup locked in a $20M Series C extension, led by Battery Ventures, boosting their valuation to $1.1B, nearly double what it was three months ago. That’s not hype. That’s momentum strapped to a JADC2 compliant rocket. Big congrats to Grant Demaree, CEO and West Point grad who…

There’s “shipping code,” and then there’s reshaping the way infrastructure gets written, automated, and trusted, line by line, PR by PR. Digger isn’t just building dev tools. They’re cracking open the Terraform playbook and piping in AI where it actually makes sense: inside the pull request, where infrastructure meets risk, cost, and reality. Today, Digger just dropped a seismic $3.6M seed round led by Initialized Capital, with an ensemble cast of elite operators joining the table, Datadog’s Olivier Pomel, Sentry’s David Cramer, WorkOS’s Michael Grinich, Resend’s Zeno Rocha, Looker’s Ben Porterfield, Percona’s Peter Zaitsev, OAuth’s Eran Sandler, motiveforce’s Oana Olteanu,…

What do you get when you mix AI, climate urgency, and a 360-degree view of chaos before it becomes catastrophe? You get Pano AI, the San Francisco-based climate tech company that just raised $44 million in Series B funding to scale global wildfire detection like it’s deploying a tactical network, not a weather app. Founded by Sonia Kastner (CEO) and Arvind Satyam (Chief Commercial Officer), Pano AI isn’t playing the “move fast, break things” game. They’re moving precisely, watching everything, and preventing the break before it happens. With this round led by Giant Ventures, and heavy hitters like Liberty Mutual…

If you’ve ever tried navigating the pharmaceutical rebate maze blindfolded, you know it’s not just inefficient, it’s expensive. And not just for pharma companies. Patients feel it. Providers feel it. Hell, even the spreadsheets feel it. Enter RIS Rx, the Newport Beach disruptors turning gross-to-net revenue leakage from an industry headache into an opportunity for transformation. Founded in 2020 by two PharmDs who got tired of watching affordability programs hemorrhage value, RIS Rx isn’t another “healthtech startup.” It’s a quiet killer in a $90B battleground, armed with software precision and pharmacist-built insight. Gerard Rivera, PharmD, the company’s CEO, and Stephen…